147 related articles for article (PubMed ID: 37675621)
1. Effectiveness and safety of human type 5 recombinant adenovirus (H101) in malignant tumor with malignant pleural effusion and ascites: A multicenter, observational, real-world study.
Wang B; Zhong C; Liao Z; Wang H; Cai X; Zhang Y; Wang J; Wang T; Yao H
Thorac Cancer; 2023 Oct; 14(30):3051-3057. PubMed ID: 37675621
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of recombinant human endostatin adenovirus in a mouse model of malignant pleural effusion.
Fang F; Chen P; Wu X; Yang L; Yang X; Xi ZX; Zhou BW; Zhou XK; Qian ZY; Xiao B; Wei YQ
J Cancer Res Clin Oncol; 2009 Sep; 135(9):1149-57. PubMed ID: 19219619
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
[TBL] [Abstract][Full Text] [Related]
5. Intrapleural infusion of tumor cell-derived microparticles packaging methotrexate or saline combined with pemetrexed-cisplatin chemotherapy for the treatment of malignant pleural effusion in advanced non-squamous non-small cell lung cancer: A double-blind, randomized, placebo-controlled study.
Dong X; Huang Y; Yi T; Hu C; Gao Q; Chen Y; Zhang J; Chen J; Liu L; Meng R; Zhang S; Dai X; Fei S; Jin Y; Yin P; Hu Y; Wu G
Front Immunol; 2022; 13():1002938. PubMed ID: 36275698
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of a new score using serum alkaline phosphatase and pleural effusion lactate dehydrogenase for patients with malignant pleural effusion.
Shi XY; Yi FS; Wang Z; Qiao X; Zhai K
Thorac Cancer; 2020 Feb; 11(2):320-328. PubMed ID: 31837116
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal infusion of recombinant human endostatin improves prognosis in gastric cancer ascites.
Zhan Z; Wang X; Yu J; Zheng J; Zeng Y; Sun M; Peng L; Guo Z; Chen B
Future Oncol; 2022 Mar; 18(10):1259-1271. PubMed ID: 35114805
[TBL] [Abstract][Full Text] [Related]
8. Better effect of intrapleural perfusion with hyperthermic chemotherapy by video-assisted thoracoscopic surgery for malignant pleural effusion treatment compared to normothermic chemoperfusion of the pleural cavity.
Cao Y; Zhang Q; Huang Z; Chai Z; Liu J; Wang J; Sun Z; Zhao T; Wang G; Chen G; Han Y; Li Q; Hong X
Cancer Med; 2022 Jan; 11(2):348-357. PubMed ID: 34854253
[TBL] [Abstract][Full Text] [Related]
9. Quality assessment of the guidelines for the management of malignant pleural effusions and ascites.
Li JX; Shi YM; An LY; Yang JX; Qi YX; Yang T; Cen YY; Lin YY; Sun DL
World J Surg Oncol; 2020 Dec; 18(1):331. PubMed ID: 33308239
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Recombinant Human Adenovirus Type 5 (H101) in Persistent, Recurrent, or Metastatic Gynecologic Malignancies: A Retrospective Study.
Zhang J; Zhang Q; Liu Z; Wang J; Shi F; Su J; Wang T; Wang F
Front Oncol; 2022; 12():877155. PubMed ID: 35574359
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic Value of Six Tumor Markers for Malignant Pleural Effusion in 1,230 Patients: A Single-Center Retrospective Study.
Fan X; Liu Y; Liang Z; Wang S; Yang J; Wu A
Pathol Oncol Res; 2022; 28():1610280. PubMed ID: 35515016
[No Abstract] [Full Text] [Related]
12. Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response.
Zhang Y; Qian L; Chen K; Gu S; Wang J; Meng Z; Li Y; Wang P
Mol Ther Oncolytics; 2022 Jun; 25():31-42. PubMed ID: 35399603
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of intrapleural hyperthermic perfusion in patients with malignant pleural effusion undergoing video-assisted thoracic surgery: a single-arm clinical trial.
Wang X; Kong M; Jin J; Lin Y; Jia L; Ye M
J Thorac Dis; 2022 May; 14(5):1497-1503. PubMed ID: 35693629
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of bevacizumab combined with cisplatin in the treatment of malignant pleural effusion and ascites caused by lung cancer: a randomized trial.
Zhou Z; Li H; Hu D; Xie L
Ann Palliat Med; 2021 Oct; 10(10):10575-10583. PubMed ID: 34763504
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological Profile of Myelomatous Pleural Effusion: Single-center Real-world Experience and Review of Literature.
Yanamandra U; Deo P; Sahu KK; Nampoothiri RV; Gupta N; Prabhakaran A; Dhibhar DP; Khadwal A; Prakash G; Sachdeva MUS; Lad D; Varma N; Varma S; Malhotra P
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):183-189.e1. PubMed ID: 30704934
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of efficacy and safety for recombinant human adenovirus-p53 in the control of the malignant pleural effusions via thoracic perfusion.
Biaoxue R; Hui P; Wenlong G; Shuanying Y
Sci Rep; 2016 Dec; 6():39355. PubMed ID: 27976709
[TBL] [Abstract][Full Text] [Related]
17. Thymidine kinase 1 concentration in pleural effusion is a diagnostic marker and survival predictor for malignant pleural effusion.
Tian T; Li J; Hu W; Sun C; Zhou J
J Clin Lab Anal; 2019 Jul; 33(6):e22901. PubMed ID: 30985967
[TBL] [Abstract][Full Text] [Related]
18. Laboratory Discrimination Between Neutrophilic Malignant and Parapneumonic Pleural Effusions.
Lee J; Lee YH; Seo H; Lee H; Kim YK; Yoo SS; Lee SY; Cha SI; Park JY; Kim CH
Am J Med Sci; 2019 Aug; 358(2):115-120. PubMed ID: 31331448
[TBL] [Abstract][Full Text] [Related]
19. mRNA markers associated with malignant pleural effusion.
Hsu SC; Chang SY; Hwang YT; Terng HJ; Tsai CL; Shen CH; Huang SK; Chian CF
Sci Rep; 2023 Apr; 13(1):6677. PubMed ID: 37095178
[TBL] [Abstract][Full Text] [Related]
20. Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites.
Huang XE; Wei GL; Huo JG; Wang XN; Lu YY; Wu XY; Liu J; Xiang J; Feng JF
Asian Pac J Cancer Prev; 2013; 14(4):2611-4. PubMed ID: 23725184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
